 This study examined the effects of delayed intravitreal injections, IVIS, due to the COVID-19 pandemic on patients with neovascular age-related macular degeneration, NAMD. Patients were divided into two groups based on whether or not they had skipped their scheduled IVIS during the pandemic period. Those who skipped their IVIS experienced a greater decline in vision than those who continued with their treatment plan. However, both groups showed similar improvements in vision after six months. Additionally, no significant differences were found in the development of atrophy or fibrosis between the two groups. This suggests that a risk-based selection strategy and a rescue therapy can be used to minimize the long-term outcomes of an interruption of the treatment protocol in patients with NAMD. This article was authored by Marco Nascisi, Francesco Pozzo-Giofrida, Paolo Millele, and others.